Investor profile
Novartis Venture Fund has backed 22 European tech companies across 29 funding rounds between 2000 and 2025, joining rounds totalling €1.2B. Most active in Healthtech. Data as of 6 Aug 2026.
Also recorded as: Novartis
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| 3 |
| €92M |
| Citryll | Netherlands | 1 | €85M |
| F2G | UK | 2 | €82M |
| GenSight Biologics | France | 2 | €64M |
| NRG Therapeutics | UK | 1 | €58M |
| CatalYm | Germany | 1 | €50M |
| Oculis | Switzerland | 1 | €47M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Vivet Therapeutics | France | 1 | €38M |
| Epsilogen | UK | 1 | €37M |
| Atlas Genetics | UK | 1 | €32M |
| Enterprise Therapeutics | UK | 1 | €30M |
| Ayala Pharmaceuticals | Israel | 1 | €27M |
| Inflazome | Ireland | 1 | €15M |
| MyoPowers Medical Technologies | Switzerland | 1 | €11M |
| Deciphex | Ireland | 1 | €11M |
| Rappta Therapeutics | Finland | 1 | €9.0M |
| LoQus23 Therapeutics | UK | 1 | €8.3M |
| €85M |
| 2024-12 |
| Merus | Series C | €73M | 2015-08 |
| NRG Therapeutics | Series B | €58M | 2025-09 |
| F2G | Growth/Late | €55M | 2016-06 |
| CatalYm | Series C | €50M | 2022-11 |
| SpliceBio | Series A | €50M | 2022-02 |
| Oculis | Series C | €47M | 2021-05 |
